AstraZeneca: Breast Neoplasms trials

The registry lists 198 Breast Neoplasms studies with AstraZeneca as lead sponsor. 20 are open to participants now and 41 have results posted.

Phase 1 42Phase 2 43Phase 3 46Phase 4 7No phase 72(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Breast Cancer Real-World Insights and Decision Guidance Evaluation in Hong KongNot yet recruitingNCT07916714
• A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.RecruitingNCT07743944
• SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBCNot yet recruitingNCT07701070
• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingNCT07647328Phase 3
• BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine TherapyRecruitingNCT07597993
• HER2-positive Metastatic Breast Cancer in KazakhstanRecruitingNCT07593196
• Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingNCT07427394Phase 2
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruitingNCT07205822Phase 3
• Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST CancerRecruitingNCT07070128
• CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREARecruitingNCT06927648
• REBECCA Real-world Early BrEast CanCer mAnagementRecruitingNCT06856343
• Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerRecruitingNCT06727227
• Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.RecruitingNCT06417801
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingNCT06103864Phase 3
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationRecruitingNCT05877599Phase 1
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingNCT05774951Phase 3
• PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanRecruitingNCT05573893
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT05417594Phase 1/2
• A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingNCT05123482Phase 1/2
• Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast CancerCompletedNCT05498155Phase 2Results posted
• Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive, not recruitingNCT05113251Phase 3Results posted
• A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Active, not recruitingNCT05104866Phase 3Results posted
• A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerActive, not recruitingNCT04739761Phase 3Results posted
• A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast CancerCompletedNCT04588298Phase 2Results posted
• Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerActive, not recruitingNCT04494425Phase 3Results posted
• Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast CancerCompletedNCT04330040Phase 4Results posted
• Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerActive, not recruitingNCT04305496Phase 3Results posted
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingNCT03742102Phase 1/2Results posted
• To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.CompletedNCT03286842Phase 3Results posted
• A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy SubjectsCompletedNCT02780713Phase 1Results posted
• A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.Active, not recruitingNCT02734004Phase 1/2Results posted
• A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast CancerTerminatedNCT02561832Phase 1Results posted
• A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCompletedNCT02447328Phase 4Results posted
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerActive, not recruitingNCT02032823Phase 3Results posted
• Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.CompletedNCT02000622Phase 3Results posted
• Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer PatientsCompletedNCT01625286Phase 1/2Results posted
• AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerCompletedNCT01597388Phase 1Results posted
• Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast CancerCompletedNCT01446159Phase 2Results posted
• Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer WomenCompletedNCT01300351Phase 3Results posted
• Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsCompletedNCT01202591Phase 1/2Results posted
• Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast CancerTerminatedNCT01151215Phase 2Results posted
• Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast CancerCompletedNCT01073865Phase 3Results posted
• Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)CompletedNCT00900627Phase 1/2Results posted
• Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast CancerCompletedNCT00679783Phase 2Results posted
• Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal TreatmentCompletedNCT00605267Phase 3Results posted
• Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone DiseaseCompletedNCT00558272Phase 2Results posted
• Liver Safety Under Upfront Arimidex vs TamoxifenCompletedNCT00537771Phase 4Results posted
• Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast CancerCompletedNCT00494234Phase 2Results posted
• AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.CompletedNCT00454805Phase 2Results posted
• Iressa Follow-up TrialCompletedNCT00357734Phase 3Results posted
• Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast CancerCompletedNCT00357110Phase 2Results posted
• Arthralgia During Anastrozole Therapy for Breast CancerCompletedNCT00323479Phase 4Results posted
• Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal WomenCompletedNCT00322348Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mgCompletedNCT00313170Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgCompletedNCT00305448Phase 2Results posted
• Secondary Adjuvant Long Term Study With ArimidexCompletedNCT00295620Phase 3Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerCompletedNCT00274469Phase 2Results posted
• Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast CancerCompletedNCT00259090Phase 2Results posted
• Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination TherapyCompletedNCT00256698Phase 3Results posted
• Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Active, not recruitingNCT00099437Phase 3Results posted
• Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + FulvestrantCompletedNCT07008963
• Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast CancerCompletedNCT06827132
• An Ophthalmic Safety Study in Patients With Breast CancerActive, not recruitingNCT06767462
• A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingNCT06764186Phase 3
• Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsActive, not recruitingNCT06635447Phase 3
• A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsCompletedNCT06547164Phase 1
• Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsActive, not recruitingNCT06429761Phase 4
• HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in CanadaCompletedNCT06386263
• A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsActive, not recruitingNCT06271837Phase 2
• Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in BrazilTerminatedNCT06231693
• A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingNCT06188520Phase 1/2
• UNFOLD Study EgyptCompletedNCT06188494
• NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer PatientsCompletedNCT06131424
• HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation CouncilCompletedNCT06125314
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingNCT06112379Phase 3
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingNCT05952557Phase 3
• A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiAActive, not recruitingNCT05939128
• HER2-low Unresectable and/or Metastatic Breast Cancer in RussiaCompletedNCT05913440
• HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in RussiaCompletedNCT05905939
• LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)CompletedNCT05677308
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Active, not recruitingNCT05629585Phase 3
• An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast CancerTerminatedNCT05592483
• A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleCompletedNCT05551897Phase 1
• Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersCompletedNCT05438303Phase 1
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Active, not recruitingNCT05374512Phase 3
• A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833CompletedNCT05364255Phase 1
• A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
• Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer PatientsCompletedNCT05203458
• Zoladex® 10.8 BC RWSCompletedNCT05184257
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingNCT04964934Phase 3
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3
• Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast CancerCompletedNCT04857619
• AZD9833 China PK StudyCompletedNCT04818632Phase 1
• Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low StatusCompletedNCT04807595
• Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active, not recruitingNCT04784715Phase 3
• A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the BodyCompletedNCT04712396Phase 1
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingNCT04711252Phase 3
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingNCT04556773Phase 1